[Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application].
We studied whether lymphokine-activated killer (LAK) cells and cytotoxic T lymphocytes (CTL) were capable of being induced in vitro from peripheral blood lymphocytes of patients with brain tumor. The LAK cells were generated by culturing recombinant IL-2 with peripheral blood lymphocytes. The culture was continued for 72 hours; then cytotoxicity to Hela cell was examined by 4-hr 51Cr release assay. LAK cells were induced from lymphocytes of patients with brain tumor, but the cytotoxicity was rather less than that of healthy subjects, and it was accompanied by clinical deterioration. CTL was generated by co-culture of patient's peripheral blood lymphocytes and autologous brain tumor cells with addition of rIL-2. The cytotoxicity to autologous and allogenic brain tumor cells was examined by 16-hr51Cr release assay. The cytotoxicity to autologous tumor was approximately 30-40%, and there was cross reaction to allogenic tumor cells. The adoptive transfer of CTL to four patients was performed. One patient improved clinically, and on CT scan, growth of the tumor appeared to have been reduced.
Moriki
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000637:transplantation*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000637:transplantation; D014407:Tumor Cells, Cultured / Q000473:pathology
D007376:Interleukin-2; D011994:Recombinant Proteins